SpikImm highlights the readiness of its proprietary monoclonal antibody platform to rapidly address emerging viral threats, including current concerns surrounding potential hantavirus outbreaks.
Originally developed and validated through the company’s work on SARS-CoV-2, the platform is designed to accelerate the discovery and development of long-acting prophylactic monoclonal antibodies that can provide immediate and lasting protection, particularly for vulnerable or immunocompromised populations.
Through collaborations with leading academic research centers such as the Institut Pasteur, SpikImm aims to strengthen preparedness against future infectious disease outbreaks while continuing to advance its clinical-stage pipeline, including SPK004 for the prevention of BK virus reactivation in renal transplant patients.